
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Probiotix Health Plc | AQSE:PBX | Aquis Stock Exchange | Ordinary Share | GB00BLNBFR86 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.50 | -4.76% | 10.00 | 7.00 | 11.00 | 10.50 | 9.00 | 10.50 | 20,000 | 16:29:58 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
29/2/2024 10:30 | JMF, I have sent Walbrook another email today. As below. Hello again, Time marches on and indeed the month of March starts tomorrow. If Steen is going to update shareholders on his plans for Probiotix in 2024, he needs to hurry up! Please could you get him to set a date for this soon. Many thanks | ![]() m4rtinu | |
29/2/2024 07:21 | Lack of any update for 2023 doesn't bode well imp | ![]() jmf69 | |
27/2/2024 17:44 | Nice to see you 🙉 To see you nice ... | ![]() institutional investments | |
27/2/2024 17:38 | Evening all | ![]() institutional investments | |
26/2/2024 12:51 | From Lse boardhTtps://www.sym | ![]() jmf69 | |
26/2/2024 07:46 | Partnership with SymbioPharm, Germany. Also covers Austria and Switzerland. Their (apparent) reputation and access to outlets: pharmacy, online should help sales. | ![]() m4rtinu | |
07/2/2024 10:38 | New position advertised. | ![]() m4rtinu | |
05/2/2024 07:44 | PBX at Probiota event this Wed to Fri. As are Opti. | ![]() m4rtinu | |
31/1/2024 20:32 | Agreed M$RTIN. However, I'm now inclined to stick to the facts in an official RNS rather than SOH or SA rhetoric. The key is marketing and none of the 3 have any spend for it There within lies one of the issues. | pj 1 | |
31/1/2024 20:22 | Don't think products or science are in question. Just be good to make a profitable business out of it. | ![]() m4rtinu | |
31/1/2024 15:52 | JMF - in my post 33 above, I said about an email I sent to Walbrook re news update. That was early Dec. Sent them a follow up today. They still have no date for Steen to set his plans for 24 in IM presentation. | ![]() m4rtinu | |
31/1/2024 14:56 | That's what I'm concerned about. Lack of news or update on 2023. | ![]() jmf69 | |
31/1/2024 11:20 | Yes. Steen is doing a good job on spending! Let's have some revenue news please. | ![]() m4rtinu | |
31/1/2024 09:23 | Another new member of the Probiotix team | ![]() jmf69 | |
11/1/2024 21:37 | "Enlightenment welcome - but spare everyone the private blag, and put it here" ..... | ![]() institutional investments | |
11/1/2024 21:36 | PS, please don't say the opti 46% was the PI share FFS 😂 | ![]() institutional investments | |
11/1/2024 21:35 | Looking forward to it Il stick to basics as it's not over me head Back with those soon | ![]() institutional investments | |
11/1/2024 21:32 | How much did Opti raise from shareholders since inception? Surely inception itself was a few million raised? And then other raises from PI via asset and cash distribution spun out to other listings . Dunno what total that is So if OPti paid £250K towards the £1 million CLN and OHara and family paid circa 300K towards CLN equalling roughly 60% of 1 million , I guess I'm right to assume the float weighting for them v the free shares to PI opti investors is weighted accordingly ? Re PI holding far more float with free shares ? Yes or no? Can somebody help me not need break out the calculator so we can crack on? | ![]() institutional investments | |
11/1/2024 21:23 | Once we know the numbers, we can crack on with a 'fair' analysis | ![]() institutional investments | |
11/1/2024 21:22 | And what percentage of float was free shares for PI opti holders? | ![]() institutional investments |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions